Beximco Pharmaceuticals Limited — Results for the year ended 30 June 2026

(LSE:BXP) Beximco Pharmaceuticals Limited reported net revenue of BDT 56,265.9m for the year ended 30 June 2026, representing a 14.5% year-on-year increase. Domestic sales grew by 15.1% to BDT 51,852.5m, while export sales increased by 8.3% to BDT 4,413.4m. Profit after tax rose 30.9% to BDT 9,160.8m (£56.6m). Earnings per share increased to BDT 20.17, compared to BDT 15.56 in the previous year (2024-25). The board has recommended a 60% cash dividend, equivalent to BDT 6.00 per share. Cash and cash equivalents at year-end strengthened to BDT 6,668.0m, up from BDT 1,700.1m in the prior period. Operating cash flow for the year was BDT 9,514.8m. During the year, Beximco Pharma launched Triko (a generic version of Trikafta), Eletriptan in the US, and Sotalol in Canada. The company also completed multiple international product registrations, which supported revenue momentum. The board's dividend recommendation reflects the company's strong financial performance. The launch of new products and successful international registrations contributed to the company's growth. The increase in cash and cash equivalents demonstrates improved liquidity. The rise in operating cash flow indicates strong underlying business operations. The company continues to expand its international presence through new product launches and registrations.

Q3 Financial Results 2025-26

(LSE/AIM:BXP) Beximco Pharmaceuticals PLC announced its unaudited financial results for the third quarter and nine months ended 31 March 2026, reporting net sales for the nine months increased 13.1% to Bangladesh Taka ("BDT") 41,428.0m / £256.9m compared to BDT 36,622.0m / £235.0m in the previous year. Domestic sales rose 14.4% to BDT 38,459.2m / £238.5m, while export sales decreased 1.2% to BDT 2,968.8m / £18.4m. Profit after tax for the nine months increased 34.0% to BDT 7,048.6m / £43.7m, up from BDT 5,261.0m / £33.8m. For the third quarter ended 31 March 2026, net sales increased 8.1% to BDT 13,627.8m / £84.5m, and profit after tax increased 30.6% to BDT 2,254.4m / £14.0m. Net asset value (NAV) per share as at 31 March 2026 was Tk. 134.60, compared to Tk. 115.21 as at 31 March 2025. The company projects its aspiration to be among the most admired companies in the region.

Half Year Results 2025-26

(LSE/AIM:BXP) Beximco Pharmaceuticals PLC announced its unaudited financial results for the six months ended 31 December 2025, reporting net revenue increased 15.8% to Bangladesh Taka ("BDT") 27,800.2m / £170.2m compared to BDT 24,013.4m / £161.5m in the previous year. Domestic sales rose 15.6% to BDT 25,743.1m / £157.6m, while export sales increased 17.5% to BDT 2,057.1m / £12.6m. Profit after tax grew 35.6% to BDT 4,794.2m / £29.3m, up from BDT 3,535.0m / £23.8m. For the second quarter ended 31 December 2025, net sales increased 13.9% to BDT 14,005.3m / £85.7m and profit after tax rose 29.8% to BDT 2,392.9m / £14.6m. The company reported total assets of 79,073,801, equity attributable to owners of the company at 57,828,336, and net asset value (NAV) per share of Tk. 129.63 as at 31 December 2025. The company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines.

Q1 Financial Results 2025-26

(LSE/AIM:BXP) Beximco Pharmaceuticals PLC announced its unaudited results for the three-month period ended 30 September 2025, reporting net revenue increased 17.8% to Bangladesh Taka ("BDT") 13,794.8m / £85.0m (2023-24: BDT 11,714.0m / £74.0m). Domestic sales increased 17.8% to BDT 13,717.4m / £84.5m, while export sales increased 5.4% to BDT 77.4m / £0.5m. Profit after tax rose 41.9% to BDT 2,401.3m / £14.8m (2023-24: BDT 1,691.9m / £10.7m). Net asset value (NAV) per share was Tk. 124.34 as at 30 September 2025, up from Tk. 111.25 a year earlier. Cash generated from operations was 3,324,094 Taka for July-September 2025, and net cash generated from operating activities was 2,737,846 Taka. The company had closing cash and cash equivalents of 2,649,120 Taka as at 30 September 2025. The company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines.

Q3 Financial Results 2024-25

(LSE/AIM:BXP) Beximco Pharmaceuticals PLC announced its unaudited financial results for the third quarter and nine months ended 31 March 2025, reporting net revenue for the nine months increased 10.8% to Bangladesh Taka ("BDT") 36,622.0m / £235.0m (2023-24: BDT 33,050.9m / £239.1m). Domestic sales rose 8.5% to BDT 33,617.7m / £215.7m, while export sales increased 45.6% to BDT 3,004.3m / £19.3m. Profit after tax for the nine months increased 20.3% to BDT 5,261.0m / £33.8m (2023-24: BDT 4,374.7m / £31.6m). For the third quarter ended 31 March 2025, net revenue increased 14.8% to BDT 12,608.6m / £80.9m, and profit after tax increased 26.3% to BDT 1,726.0m / £11.1m. The company reported net asset value (NAV) per share of Tk. 115.21 as at 31 March 2025. Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others, and it has a geographic footprint in more than 50 countries.

First patients access affordable CF medicine

(LSE/AIM:BXP) Beximco Pharmaceuticals announced that the first patients have gained access to its affordable, generic cystic fibrosis medicine, Triko, which costs over $350,000 less per patient per year than the patented version. The generic version is priced at $6,375 for children and $12,750 per year for adults, representing a 96% reduction against the US list price of $370,000 per year for the originator product. Patients from Slovakia, South Africa, Qatar, USA, UK, and Bangladesh collected the first doses of Triko at a ceremony in Dhaka, Bangladesh. Beximco's BEXDECO, a generic version of ivacaftor, is also available at $5 per tablet. With a dose reduction protocol pioneered by South African CF clinicians, the cost to treat a child for a year drops to less than $2000. The company projects that supply will be managed on a named-patient basis through the CF Buyers' Club, with plans to progressively expand access to the broader global CF community as manufacturing capacity is scaled. At this price point, 58 children can receive treatment for the same cost as treating one child with the branded medicine.

BEXIMCO PHARMACEUTICALS LIMITED